Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Infectious Disease Clear all
Completed No phase listed Observational

Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV

NCT00016783
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2013 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 3 Interventional

A Study Of Diflucan In Children With Ringworm Of The Scalp

NCT00645242
View directory record Official record
Conditions
Tinea Capitis
Interventions
fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 12 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
28
States / cities
Montgomery, Alabama • Little Rock, Arkansas • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jun 11, 2026, 1:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

NCT02061800
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jun 11, 2026, 1:58 AM EDT
Not listed No phase listed Observational

Airway Microbiome Changes After Artificial Airway Exchange in Critically-ill Pediatric Patients.

NCT06201130
View directory record Official record
Conditions
Tracheostomy, Endotracheal Tube, Ventilator Associated Pneumonia, Tracheitis, Microbial Colonization, Pediatric Infectious Disease, Pediatrics
Interventions
Suctioning of artificial airway
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
0 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke

NCT02489708
View directory record Official record
Conditions
Asthma, Smoking Cessation
Interventions
Cessation Counseling
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 4 Interventional

Study of Wound Packing After Superficial Skin Abscess Drainage

NCT00746109
View directory record Official record
Conditions
Abscess, Skin Diseases, Infectious, Boils, Furuncle, Carbuncle, Folliculitis, Cellulitis, Wounds
Interventions
Wound packing, NoPacking
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 24 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2011 · Synced Jun 11, 2026, 1:58 AM EDT
Active, not recruiting Not applicable Interventional Results available

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

NCT05236764
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection
Interventions
CliniMACS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pediatric Subjects With Tinea Corporis

NCT02227290
View directory record Official record
Conditions
Tinea Corporis
Interventions
Naftin Cream, Placebo Cream
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
14
States / cities
Tucson, Arizona • Encino, California • Fremont, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Not applicable Interventional

An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies

NCT00002118
View directory record Official record
Conditions
HIV Infections
Interventions
Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 11 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Cellphone Based Otoscopy in Pediatric Patients

NCT04296448
View directory record Official record
Conditions
Ear Infection, Pediatric Disease, Acute Otitis Media
Interventions
Cellscope
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 1Phase 2 Interventional

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

NCT00084058
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Birmingham, Alabama • Long Beach, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 11, 2026, 1:58 AM EDT
Recruiting No phase listed Observational

RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age

NCT06273748
View directory record Official record
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
Meyer Children's Hospital IRCCS
Other
Eligibility
1 Year to 16 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
3
States / cities
Kansas City, Kansas • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adolescent Sexually Transmitted Infection Screening in the Emergency Department

NCT03715335
View directory record Official record
Conditions
Gonorrhea, Chlamydia
Interventions
Targeted STI Screening, Universally Offered STI Screening
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 21 Years
Enrollment
98,413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
5
States / cities
Aurora, Colorado • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Xofluza-Wearables Feasibility-Study

NCT06161454
View directory record Official record
Conditions
Infection, Coronavirus, Infections, Influenza, Transplant, Infection Viral
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
498 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 11, 2026, 1:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Collection Biorepository for Liver Disease Research

NCT03025074
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jun 11, 2026, 1:58 AM EDT
Withdrawn Phase 2 Interventional

Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.

NCT02567149
View directory record Official record
Conditions
Warts
Interventions
Cidofovir
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

NCT00116662
View directory record Official record
Conditions
Warts
Interventions
Resiquimod
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
3 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Newnan, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2007 · Synced Jun 11, 2026, 1:58 AM EDT
Withdrawn Not applicable Interventional

Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)

NCT01814293
View directory record Official record
Conditions
Acute Upper Respiratory Infection, Signs and Symptoms
Interventions
Handheld humidifier
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 4 Interventional

Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections

NCT00001658
View directory record Official record
Conditions
Autoimmune Disease, Mental Disorder, Obsessive Compulsive Disorder, Streptococcal Infection, Tic Disorder
Interventions
Amoxicillin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group

NCT00000815
View directory record Official record
Conditions
HIV Infections, Measles
Interventions
Attenuvax, M-M-R-II
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 7 Months
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
43
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

NCT01506141
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT, Elaprase
Drug
Lead sponsor
Takeda
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Aztreonam Lysine for Pseudomonas Infection Eradication Study

NCT01375049
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes

NCT00001438
View directory record Official record
Conditions
HIV Infections, Immunologic Deficiency Syndromes, Lymphoproliferative Disorders
Interventions
all-trans-retinoic acid with IFN-alpha2a
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 11, 2026, 1:58 AM EDT